Navigation Links
Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine
Date:6/11/2008

is, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kirin, and the Statens Serum Institut.

The Company's leading product, a prophylactic vaccine against Japanese Encephalitis, successfully concluded pivotal Phase III clinical trials in 2006. The Market Authorization Application (MAA) in Europe as well as the Biological License Application (BLA) with the US Food and Drug Administration (FDA) for the use of the vaccine to prevent Japanese Encephalitis were submitted in December of 2007. The licensure application to TGA (Therapeutic Goods Administration) in Australia was submitted in February of 2008.

The Company's broad development pipeline includes a partnered S. aureus vaccine in Phase II, a therapeutic vaccine against Hepatitis C in Phase II, a Pseudomonas vaccine in Phase II, a partnered Tuberculosis vaccine (Phase I/II), and five products focused on infectious diseases in preclinical development.

Intercell is listed on the Prime Market of the Vienna Stock Exchange under the symbol "ICLL".
ISIN: AT0000612601

For more information on Intercell, please visit: http://www.intercell.com

Important Additional Information Regarding the Proposed Merger

In connection with the proposed transaction, on May 14, 2008, Iomai Corporation filed a preliminary proxy statement for its stockholders with the Securities and Exchange Commission (SEC). Iomai Corporation will be filing a definitive proxy statement for its stockholders and other documents regarding the proposed transaction with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, IOMAI STOCKHOLDERS AND INVESTORS ARE URGED TO CAREFULLY READ THE PRELIMINARY PROXY STATEMENT AND, WHEN IT BECOMES AVAILABLE, THE DEFINITIVE PROXY STATEMENT AS WELL AS ANY OTHER RELEVANT MATERIALS, IN THEIR ENTIRETY BECAUSE THE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND IOMAI. Investors and stockholders may obtai
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
5. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
6. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
7. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
(Date:5/21/2013)... STAAR Surgical Company (NASDAQ: STAA ... invasive ophthalmic products, today announced that it will participate ... recent financial results and business developments with investors and ... the 38 th Annual Deutsche Bank 2013 Healthcare ... Westin Waterfront Hotel on Wednesday, May 29, 2013 at ...
(Date:5/20/2013)... 2013   , ... ministers gather to address the large physical and economic ... disorders (MNDs) affect 700 million people annually and account ... ,Do You Mind?, helps patients, family members, ... play to collectively address MNDs , Today ...
Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4STAAR Surgical To Present At Upcoming Investor Conferences 2Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2
... ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 ... of an agreement to provide extended bioinformatics genomics services ... at Ambry. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO ... team at Ambry has been providing genomics solutions on ...
... , DOYLESTOWN, Pa., ... Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced ... opportunities to develop prescription pharmaceutical and OTC products and has ... primarily on the OTC/Personal Care marketplace, which may include but ...
Cached Medicine Technology:Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3
(Date:5/21/2013)... , , MONDAY, May 20 (HealthDay News) -- Long-acting ... chronic obstructive pulmonary disease (COPD) may raise the ... new large Canadian study reveals. The finding ... prescribed long-acting bronchodilators -- either anticholinergics (such as ... are commonly used to relieve the shortness of ...
(Date:5/21/2013)... News) -- Racial disparities exist in the treatment of ... States, according to a large new study. Although ... of their initial treatment, researchers found that blacks were ... in the early stages of the disease. Hispanics were ... stage 2 disease than white patients. "In our ...
(Date:5/21/2013)... ─ The negative effects of poorly controlled asthma ... urban schoolchildren has been confirmed in a new ... that missed sleep and school absences are important ... is the first to explore the associations between ... time, prospectively, using both objective and subjective ...
(Date:5/21/2013)... approach to obstructing the runaway inflammatory response implicated ... in a Phase IIa clinical trial, according to ... presented at the American Thoracic Society 2013 International ... New England Journal of Medicine . , The ... safety of the monoclonal antibody, dupilumab, in patients ...
(Date:5/21/2013)... Goderich, Ontario, CA (PRWEB) May 21, 2013 ... the fitness boot camp business Fit Body Boot ... Meltdown Challenge starting June 3rd at its Goderich fitness ... Fit Body Boot Camp’s 1,000 lb. Meltdown Challenge’s goal is ... total of 1,000 pounds in 28 days. The fee ...
Breaking Medicine News(10 mins):Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2Health News:Asthma symptoms impair sleep quality and school performance in children 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 3Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... 11 Wound Management,Technologies, Inc., (OTC Bulletin Board: ... potential acquisition of BioPharma Management Technologies, Inc.,a company ... pain,management products. "While we have been focusing ... products, we also have been working,to expand our ...
... Dec. 11 Barr Pharmaceuticals, Inc. (NYSE: ... Food and Drug Administration (FDA) has accepted for ... 7 Live Oral Vaccines Biologics License Application (BLA). ... development initiative and demonstrate the Company,s ability to ...
... research is declining sharply, more than 9 percent a year since ... of Pain . Pain research, as a result, now accounts ... Institutes of Health (NIH), despite the high prevalence of chronic pain ... government,s meager investment in pain research is seriously out of proportion ...
... are asking if cardiology patients receive intervention-type treatments, such as ... , In regions of the country where ... problems, patients may be receiving a treatment known as percutaneous ... to a study published online this week in the journal ...
... funding source to public health , ... Prevention today unveiled health reform recommendations to Congress that ... tackle the chronic diseases that are causing medical costs ... Under these proposals, federally funded insurance programs would provide ...
... CITY, Dec. 11 Genomma Lab Internacional,S.A.B. de ... a leading Mexican,over-the-counter ("OTC") pharmaceuticals and personal care ... personal hair care product line,Ma Evans. The ... campaign under,the brand name "Ma Evans Evolution". ...
Cached Medicine News:Health News:Wound Management Technologies, Inc. Announces Negotiations to Acquire BioPharma Management Technologies, Inc. 2Health News:Wound Management Technologies, Inc. Announces Negotiations to Acquire BioPharma Management Technologies, Inc. 3Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 2Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 3Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 4Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 5Health News:Study shows major pain research funding decline at NIH 2Health News:Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment? 2Health News:Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment? 3Health News:Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment? 4Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 2Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 3Health News:Genomma Lab Announces the Successful Launch of the Ma Evans Brand 2
... Array systems are fully automated ... fast turnaround of highly accurate ... drug monitoring (TDM) results. Using ... the easy-to-use Array® 360 performs ...
ELISA kit for detection of Rheumatoid Factor....
... create tired, dry eyes. With ACUVUE OASYS IN, ... challenging environments can make your eyes feel tired ... a computer can leave your eyes craving moisture. ... PLUS Brand Contact Lenses. It will almost ...
... Better. Introducing Disposable Bimanuals. With the ... need for quality single-use bimanuals. Oasis meets ... NEW disposable bimanuals. Single use bimanuals decrease ... time, they encompass all the advantages of ...
Medicine Products: